Report - Imetelstat Treatment Leads to Durable Transfusion ... · IMerge is an ongoing global phase 2/3 study of imetelstat in RBC TD patients with LR-MDS (IPSS Low or Int-1)4 1. Baerlocher

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form